Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

BACKGROUND: A triple‐secured plasma‐derived von Willebrand factor (pdVWF) almost devoid of factor VIII (FVIII):WILFACTIN(®), was approved in France in 2003, and then in other countries for the treatment of patients with von Willebrand disease (VWD). OBJECTIVE: To investigate long‐term safety and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Goudemand, Jenny, Bridey, Françoise, Claeyssens, Ségolène, Itzhar‐Baïkian, Nathalie, Harroche, Annie, Desprez, Dominique, Négrier, Claude, Chamouni, Pierre, Chambost, Hervé, Henriet, Céline, Susen, Sophie, Borel‐Derlon, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496521/
https://www.ncbi.nlm.nih.gov/pubmed/32445594
http://dx.doi.org/10.1111/jth.14928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496521/
https://www.ncbi.nlm.nih.gov/pubmed/32445594
http://dx.doi.org/10.1111/jth.14928

Ejemplares similares